A phase 2 trial with the anti-IGF1R mAb R1507 indicated that the treatment was safe but with limited anti-tumor activity as it in fact demonstrated only 2% of partial response and 16% of disease stabilization [182]. The gene discussed is IGF1R; the disease is neoplasm.